SLC5A2 and Arrhythmia: Bode et al. (32) showed in a rat model of HFpEF related to metabolic syndrome that rats that received the SGLT2 inhibitor Sotagliflozin exhibited improved metabolic left atrial remodeling and arrhythmia characteristics.